Arturo J MartÃ-CarvajalGeorgia SalantiPedro I. Marti-Carvajal2026-03-222026-03-22200710.1002/14651858.cd004887.pub2https://doi.org/10.1002/14651858.cd004887.pub2https://andeanlibrary.org/handle/123456789/87110Citaciones: 13We found no evidence that human recombinant activated factor VII reduces the risk of death in patients with liver disease and upper gastrointestinal bleeding. However, we made our conclusion on a single randomised clinical trial. More randomised clinical trials having low risk of bias are necessary in order to determine the role of human recombinant factor VIIa in clinical practice.enMedicineCochrane LibraryPlaceboMeta-analysisRelative riskClinical trialInternal medicineGastrointestinal bleedingRandomized controlled trialMEDLINEHuman recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseasesreference-entry